Replies to post #330594 on Anavex Life Sciences Corp (AVXL)

[WolfofMia]

All good..

Not worried at all.

[Fireman02360]

Reminds me of late 2014....everyone was complaining that INTC was trading 8 times that of NVDA. Some investors I know even bailed on NVDA and took positions in INTC. My oh my, what a mistake that was. Judging and comparing the SP of one company to another makes zero sense. Anavex will either succeed on their own or they wont. Todays share-price vs. SAVA or any other biotech wont matter, unless you looking for a quick trade. That is not how generational wealth is made. Hang tight, this will work itself out.

-Fireman

[123tom]

Both SAVA and AVXL have been
falling to try and find a finished bottom .
SAVA collapsed badly from 142 to the recent low at 39. A few weeks ago it was trying to settle down around 50 and then dropped to the 40 bottom. It has a long way to climb just to retrace the basic Fib target zone 70-80-90 area. It might be starting to make that effort now. so I dont see this 9% SAVA bounce as a strong sign that AVXL is weak by comparison. SAVA might be a nice dead cat trade for a double, 40 to 80 and get out. SAVA failed didnt it. the collapse was a result of failure. AVXL has had only success, so buying the finished AVXL bottom is what I'm looking for. I dont know if 16.55 will be the lowest bottom. The support zone here is 16.50-16.30-16.00-and down into the 15's and 14's. and IF we ever do see a market collapse we might see a plunge to the 10 /9/8 target area.
I think for investment decision safety is important now with the possibility of market crash. trimming some at the tops , raising cash to buy the collapse bottoms when it happens.
--------------------------------------------
But for right now, AVXL is volatile again zig zagging 1 dollar up and down. unchanged for direction in my view. The same support zone needs to hold (17.00-17.40) area. so far its spanning a range from peak to Bottom zones.
AVXL zig zagging

SAVA bottom at 40 ?

[RedShoulder]

AVXL vs SAVA and ANVS

1) SAVA is being sued, and apparently for good reasons.

2) SAVA's trial data has been shown to be manipulated.

3) SAVA is at least two years behind AVXL if not more for AD and SAVA is still in the recruitment stage; while AVXL is in a potentially pivotal Ph-2b/3 trial in current progress which will conclude in May.

4) AVXL extensive and deep pipeline with 11 trials listed in various stages and 6 in pre clinical. Sava has just AD.

5) A2-73 works upstream eliminating the need for SAVA's downstream drug, making it redundant and not needed.

6) AVXL has a review paper in 'Scientific Reports' a publication by 'Nature', SAVA's paper was rejected, probably because of the bogus trial data.

7) AVXL has 4 drugs that will be used in various trials, SAVA has only 1 drug.

8) AVXL's A2-73 Blarcamesine will be approved and marketed with huge revenues, while SAVA is still in trials.

ANVS is so far behind, more than 3 years on AD if not more, that I'm not going to bother laying out the case against them. AVXL will have A2-73 Blarcamesine approved and earning revenues while they will still be years behind. No competition at all.

Another day underperforming the sector

AVXL + 3.14%
SAVA + 9.53%
ANVS + 7.11%

Meanwhile while we wait for news, the only thing blanketing the news wire for the other 2 companies is Class Action Update and Shareholder Alerts from law firms. Yet we continue to underperform.

Simonizer, as you can see by the comparisons above, it is totally bewildering that SAVA has a larger Market Cap. It does not make any common sense if just a little Due Diligence is applied to both companies. SMH